Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, sistemski - imunosupresivi - benlysta navodi kao dopuna terapije kod pacijenata u dobi od 5 i više godina uz aktivnu, pozitivnu аутоантитела sistemski eritemski lupus (sle) s visokim stupnjem aktivnosti bolesti (e. pozitivna anti-ova dnk i niska razina komplementa), bez obzira na standardnu terapiju. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresivi - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alkaloid d.o.o. sarajevo - kalcijumkarbonat, magnezijumkarbonat - tableta za žvakanje - 680 mg/1 tableta+ 80 mg/1 tableta - 1 tableta za žvakanje sadrži: 680 mg kalcijum karbonat, 80 mg magnezijum karbonat, teški

Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alkaloid d.o.o. sarajevo - kalcijumkarbonat, magnezijumkarbonat - tableta za žvakanje - 680 mg/1 tableta+ 80 mg/1 tableta - 1 tableta za žvakanje sadrži: 680 mg kalcijum karbonata, 80 mg magnezijum karbonata, teškog

Montenegro - Kroeshia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu i usluge, export-import "neregelia" d.o.o. podgorica - 2,4-dihlorbenzil alkohol, amilmetakrezol - lozenga - 1.2mg + 0.6mg

Montenegro - Kroeshia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu i usluge, export-import "neregelia" d.o.o. podgorica - 2,4-dihlorbenzil alkohol, amilmetakrezol, levomentol - lozenga - 1.2mg + 0.6mg + 8mg

Montenegro - Kroeshia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu i usluge, export-import "neregelia" d.o.o. podgorica - 2,4-dihlorbenzil alkohol, amilmetakrezol, askorbinska kiselina, natrijum askorbat - lozenga - 1.2mg + 0.6mg + 33.5mg + 74.9mg

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.